The use of antipsychotic medication in child and adolescent psychiatric treatment in Denmark. A cross-sectional survey

Nordic Journal of Psychiatry

Volumn 62, Issue 6, 2008, Pages 472-480

  Deurell, Maria ^a   Weischer, Merete ^b   Katrine Pagsberg, Anne ^a   Labianca, Jette ^b  

^a BISPEBJERG HOSPITAL   (Denmark)

^b NONE   (Denmark)

Author keywords

Antipsychotics; Child and adolescent psychiatry; Cross sectional study; National survey

Indexed keywords

ANTIDEPRESSANT AGENT; CHLORPROTHIXENE; CLOZAPINE; FLUPENTIXOL; HALOPERIDOL; LEVOMEPROMAZINE; NEUROLEPTIC AGENT; OLANZAPINE; PERICIAZINE; PERPHENAZINE; PIMOZIDE; PIPAMPERONE; PSYCHOSTIMULANT AGENT; QUETIAPINE; RISPERIDONE; SEDATIVE AGENT; SULPIRIDE; ZIPRASIDONE; ZUCLOPENTHIXOL;

ADOLESCENT; ADULT; AKATHISIA; ANXIETY; ARTICLE; AUTISM; CHILD; COMBINATION CHEMOTHERAPY; CONSTIPATION; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DENMARK; DIZZINESS; DRUG USE; DYSKINESIA; DYSTONIA; ENDOCRINE DISEASE; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MONOTHERAPY; MYOCLONUS; NAUSEA; ORTHOSTATIC HYPOTENSION; PARKINSONISM; PERSONALITY DISORDER; PSYCHIATRIC DEPARTMENT; PSYCHIATRIST; QUESTIONNAIRE; SCHIZOPHRENIA; SCHIZOTYPAL PERSONALITY DISORDER; SIDE EFFECT; STUTTERING; THIRST; WEIGHT GAIN;

ADOLESCENT; ADOLESCENT PSYCHIATRY; ANTIPSYCHOTIC AGENTS; AUTISTIC DISORDER; CHILD; CHILD PSYCHIATRY; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; DENMARK; DRUG THERAPY, COMBINATION; DRUG UTILIZATION; FEMALE; HUMANS; MALE; MENTAL DISORDERS; PERSONALITY DISORDERS; SCHIZOPHRENIA; SCHIZOTYPAL PERSONALITY DISORDER;

EID: 57049178860     PISSN: 08039488     EISSN: 15024725     Source Type: Journal    
DOI: 10.1080/08039480801985096     Document Type: Article

References (29)

1. Findling, RL and McNamara, NK. (2004) Atypical antipsychotics in the treatment of children and adolescents: Clinical applications. J Clin Psychiatry, 65, pp. 30-44.
2. Olfson, M., Blanco, C., Liu, L., Moreno, C. and Laje, G. (2006) National trends in the outpatient treatment of children and adolescents with antipsychotic drugs. Arch Gen Psychiatry, 63, pp. 679-685.
3. Aparasu, RR and Bhatara, V. (2007) Patterns and determinants of antipsychotic prescribing in children and adolescents, 2003-2004. Curr Med Res Opin, 23, pp. 49-56.
4. McClellan, JM and Werry, JS. (2003) Evidence-based treatments in child and adolescent psychiatry: An inventory. J Am Acad Child Adolesc Psychiatry, 42, pp. 1388-1400.
5. Findling, RL, McNamara, NK, Branicky, LA, Schluchter, MD, Lemon, E. and Blumer, JL. (2000) A double-blind pilot study of Risperidone in the treatment of conduct disorder. J Am Acad Child Adolesc Psychiatry, 39, pp. 509-516.
6. Selskab, Dansk Psykiatrisk (1998) Behandling med antipsykotika. Klaringsrapport nr. 5
7. Gracious, BL and Findling, RL. (2001) Antipsychotic medications for children and adolescents. Pediatr Ann, 30, pp. 138-145.
8. Riddle, MA, Kastelic, EA and Frosch, E. (2001) Pediatric psychopharmacology. J Child Psychol Psychiatry, 42, pp. 73-90.
9. McCracken, JT, McGough, J., Shah, B., Cronin, P. and Hong, D. (2002) Risperidone in children with autism and serious behavioural problems. N Engl J Med, 347, pp. 314-321.
10. Papadopoulos, E., Macintyre Ii, JC, Crisom, ML, Findling, RL, Malone, RP Derivan, A. et al. (2003) Treatment recommendations for the use of antipsychotics for aggressive youth (TRAAY). Part II. J Am Acad Child Adolesc Psychiatry, 42, pp. 145-161.
11. Mehler-Wex, C., Rothenhofer, S. and Warnke, A. (2005) Atypical antipsychotics in child and adolescent psychiatry-indications apart from schizophrenia. Z Kinder Jugendpsychiatr Psychother., 33, pp. 159-168.
12. Dean, AJ, McDermott, BM and Marshall, RT. (2006) Psychotropic medication utilization in a child and adolescent mental health service. J Child Adolesc Psychopharmacol, 16, pp. 273-285.
13. Jensen, PS, Buitelaar, J., Pandina, GJ, Binder, C. and Haas, M. (2007) Management of psychiatric disorders in children and adolescents with atypical antipsychotics: A systematic review of published clinical trials. Eur Child Adolesc Psychiatry, 16, pp. 104-120.
14. Remschmidt, H., Hennighausen, K., Clement, HW, Heiser, P. and Schulz, E. (2000) Atypical neuroleptics in child and adolescent psychiatry. Eur Child Adolesc Psychiatry, 9, p. I9.
15. Toren, P., Ratner, S., Laor, N. and Weizman, A. (2004) Benefit-risk assessment of atypical antipsychotics in the treatment of schizophrenia and comorbid disorders in children and adolescents. Drug Saf., 27, pp. 1135-1156.
16. Corell, CU and Carlson, HE. (2006) Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents. J Am Acad Child Adolesc Psychiatry, 45, pp. 771-791.
17. Saito, E., Correll, CU, Gallelli, K., McMeniman, M., Parikh, UH Malhotra, AK et al. (2004) A prospective study of hyperprolactinemia in children and adolescents treated with atypical antipsychotic agents. J Child Adolesc Psychopharmacol, 14, pp. 350-358.
18. Findling, RL, Kusumakar, V., Daneman, D., Moshang, T., De Smedt, G. and Binder, C. (2003) Prolactin levels during long-term risperidone treatment in children and adolescents. J Clin Psychiatry, 64, pp. 1362-1369.
19. Blair, J., Scahill, L., State, M. and Martin, A. (2005) Electrocardiography changes in children and adolescents treated with ziprasidone: A prospective study. J Am Acad Child Adolesc Psychiatry, 44, pp. 73-79.
20. Styrelsen, Lægemiddel (2001) Rationel farmakoterapi 2.
21. Kapetanovik, S. and Simpson, GM. (2006) Review of antipsychotics in children and adolescents. Expert Opin Pharmacother, 7, pp. 1871-1885.
22. Sørensen, L. (1998) Børns og unges forbrug af psykofarmaka, psykostimulantia og antidepressiva. Ugeskr Løger, 160, pp. 7433-7437.
23. Becker Nissen, JB (2003) Thomsen PH. Brug af psykofarmaka til børn henvist til Børne- og Ungdomspsykiatrisk Hospital i Risskov. Ugeskr Læger, 165, pp. 1137-1141.
24. Johnsen, E., Svingen, GF and Jørgensen, HA. (2004) Practice regarding antipsychotic therapy: A cross-sectional survey in two Norwegian hospitals. Nord J Psychiatry, 58, pp. 313-317.
25. Sivaprasad, L., Hassan, T. and Handy, S. (2006) Survey of atypical antipsychotic medication use by child and adolescents psychiatrists. Child and Adolescent Mental Health, 11, pp. 164-167.
26. Fedorowicz, VJ and Fombonne, E. (2005) Metabolic side effects of atypical antipsychotics in children: A literature review. J Psychopharmacol, 19, pp. 533-550.
27. Pappagallo, M. and Silva, R. (2004) The effect of atypical antipsychotic agents on prolactin levels in children and adolescents. J Child Adolesc Psychopharmacol, 14, pp. 359-371.
28. Cheng-Shannon, J., McGough, JJ, Pataki, C. and McCracken, JT (2004) Second-generation antipsychotic medications in children and adolescents. J Child Adolesc Psychopharmacol, 14, pp. 372-394.
29. Fleischhaker, C., Heiser, P., Hennighausen, K., Herpertz-Dahlmann, B., Holtkamp, K. Mehler-Wex, C. et al. (2006) Clinical drug monitoring in child and adolescent psychiatry: Side effects of atypical neuroleptics. J Child Adolesc Psychopharmacol, 16, pp. 308-316.